860206-84-4

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Hydroxy-quinoline-8-carboxylic acid Methyl ester is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs and organic compounds. Its versatile chemical structure allows for the development of new pharmaceuticals with improved therapeutic properties.
Used in Antimicrobial Applications:
In the field of microbiology, 4-Hydroxy-quinoline-8-carboxylic acid Methyl ester is used as an antimicrobial agent. Its derivatives have demonstrated effectiveness against a range of microorganisms, making it a promising candidate for the development of new antimicrobial drugs to combat drug-resistant infections.
Used in Antimalarial Applications:
4-Hydroxy-quinoline-8-carboxylic acid Methyl ester is used as an antimalarial agent in the treatment of malaria. Its derivatives have shown potential in inhibiting the growth and development of Plasmodium parasites, which are responsible for causing malaria.
Used in Anticancer Applications:
In oncology, 4-Hydroxy-quinoline-8-carboxylic acid Methyl ester is used as an anticancer agent. Its derivatives have been studied for their ability to inhibit the growth and proliferation of cancer cells, making it a valuable compound in the development of novel anticancer drugs.
Used in Organic Synthesis:
4-Hydroxy-quinoline-8-carboxylic acid Methyl ester is used as a versatile building block in organic synthesis. Its unique chemical structure allows for the creation of new compounds with diverse applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 185130-13-6 methyl 2-(((2,2-dimethyl-4,6-dioxo-1 ,3-dioxan-5-ylidene)methyl)amino)benzoate 
• 134-20-3 2-carbomethoxyaniline 
• 92200-67-4 4-hydroxy-quinoline-3,8-dicarboxylic acid-3-ethyl ester-8-methyl ester 
• 478-85-3 4,5,7,8,9,12-hexahydro-pyrano[4',3':4,5]azepino[3,2,1-hi]indol-11-one 
• 875232-02-3 7,8,9,12-tetrahydro-pyrano[4',3':4,5]azepino[3,2,1-hi]indol-11-one 
• 111185-87-6 4-hydroxy-quinoline-3,8-dicarboxylic acid 
• 386207-63-2 4-hydroxyquinoline-8-carboxylic acid 

Downstream Products

• 1416440-14-6 methyl 4-chloroquinoline-8-carboxylate 
• 386207-63-2 4-hydroxyquinoline-8-carboxylic acid 
• 881744-15-6 4-(4'-methylaminoallyloxycarbamate)anilino-quinoline-8-carboxylic acid 
• 881744-14-5 methyl 4-(4'-methylaminoallyloxycarbamate)anilino-quinoline-8-carboxylate 
• 132664-48-3 methyl 4-bromo-quinoline-8-carboxylate 

Relevant academic research and scientific papers

TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS.

The present invention relates to compounds of general formula (I), tautomers, stereoisomers, N-oxides, pharmaceutically acceptable salts and pro-drug thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy: wherein: a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -N(R)2, and -SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); Y represents: an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); a 5- or 6-membered, saturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or a C3-6 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); and Z represents: an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -OH, -N(R' )2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), and -C(0)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); or an unsaturated, 5- to 10-membered mono- or bicyclic heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -OH, -N(R')2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), and -C(O)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); with the proviso: that when the compound is other than an N-oxide of formula (I), Z must be substituted by at least one substituent selected from -OH, -N(R3)2, -SO2N(R3)2 and -C(O)N(R4)2, preferably by at least one substituent selected from -OH, -SO2N(R3)2 and -C(O)N(R4)2. These compounds find particular use in the treatment and/or prevention of a disease or disorder responsive to inhibition of tankyrase 1 and/or 2, for example a disorder which is mediated by tankyrase 1 and/or 2 such as cancer.

IMMUNOMODULATORY COMPOUNDS

Disclosed are immunomodulatory compounds, pharmaceutical compositions containing them, and methods of making and using the compounds to treat diseases and disorders characterized by aberrant protein activity that can be targeted by cereblon.

RNA binding and thiolytic stability of a quinoline-containing helix-threading peptide

Helix-threading peptides (HTPs) bind selectively to sites predisposed to intercalation in folded RNA molecules placing peptide functional groups into the dissimilar grooves of the duplex. Here we report the design and synthesis of new HTPs with quinoline